TELA Bio (TELA) Net Income Growth (3y) (2021 - 2026)

TELA Bio (TELA) Net Income Growth (3y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -6.51%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 7.96%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 1.93%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 62.29%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 60.12%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn 2.38%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 280.49%
10 TELA Bio 38.36 Mn -1.18 Mn 12.52 Mn 0.61%

Historic Data

Download Data
DateValue
Mar 31, 2026 0.61%
Dec 31, 2025 2.74%
Sep 30, 2025 6.98%
Jun 30, 2025 3.87%
Mar 31, 2025 -0.26%
Dec 31, 2024 75.65%
Sep 30, 2024 2.86%
Jun 30, 2024 5.03%
Mar 31, 2024 15.21%
Dec 31, 2023 -17.01%
Sep 30, 2023 -7.81%
Jun 30, 2023 -17.39%
Mar 31, 2023 -11.09%
Dec 31, 2022 -10.82%
Sep 30, 2022 -14.30%
Jun 30, 2022 -28.92%
Mar 31, 2022 -22.41%
Dec 31, 2021 -12.87%
Sep 30, 2021 -58.67%